Anti-melanoma Activity of Forsythiae Fructus Aqueous Extract in Mice Involves Regulation of Glycerophospholipid Metabolisms by UPLC/Q-TOF MS-based Metabolomics Study

Overview

Journal Sci Rep

Specialty Science

Date 2016 Dec 20

PMID 27991567

Citations 8

Authors

Jiaolin Bao

Fang Liu

Chao Zhang

Kai Wang

Xuejing Jia

Xiaotong Wang

Meiwan Chen

Peng Li

Huanxing Su

Yitao Wang

Jian-Bo Wan

Chengwei He

Affiliations

Soon will be listed here.

Abstract

Metabolomics is a comprehensive assessment of endogenous metabolites of a biological system in a holistic context. In this study, we evaluated the in vivo anti-melanoma activity of aqueous extract of Forsythiae Fructus (FAE) and globally explored the serum metabolome characteristics of B16-F10 melanoma-bearing mice. UPLC/Q-TOF MS combined with pattern recognition approaches were employed to examine the comprehensive metabolic signatures and differentiating metabolites. The results demonstrated that FAE exhibited remarkable antitumor activity against B16-F10 melanoma in C57BL/6 mice and restored the disturbed metabolic profile by tumor insult. We identified 17 metabolites which were correlated with the antitumor effect of FAE. Most of these metabolites are involved in glycerophospholipid metabolisms. Notably, several lysophosphatidylcholines (LysoPCs) significantly decreased in tumor model group, while FAE treatment restored the changes of these phospholipids to about normal condition. Moreover, we found that lysophosphatidylcholine acyltransferase 1 (LPCAT1) and autotaxin (ATX) were highly expressed in melanoma, and FAE markedly down-regulated their expression. These findings indicated that modulation of glycerophospholipid metabolisms may play a pivotal role in the growth of melanoma and the antitumor activity of FAE. Besides, our results suggested that serum LysoPCs could be potential biomarkers for the diagnosis and prognosis of melanoma and other malignant tumors.

Citing Articles

LPCAT1 promotes melanoma cell proliferation via Akt signaling.

Wang Y, Huang Y, Wang Y, Zhang W, Wang N, Bai R Oncol Rep. 2024; 51(5).

PMID: 38551165 PMC: 10995661. DOI: 10.3892/or.2024.8726.

Protective effects of and water extract against memory deficits through the gut-microbiome-brain axis in an Alzheimer's disease model.

Kim D, Zhang T, Park S Pharm Biol. 2022; 60(1):212-224.

PMID: 35076339 PMC: 8794073. DOI: 10.1080/13880209.2022.2025860.

A rapid increase in lysophospholipids after geranylgeranoic acid treatment in human hepatoma-derived HuH-7 cells revealed by metabolomics analysis.

Shidoji Y, Iwao C Biochem Biophys Rep. 2021; 28:101176.

PMID: 34869922 PMC: 8626837. DOI: 10.1016/j.bbrep.2021.101176.

One extraction tool for extrapolation? SPME-based metabolomics of 2D, 3D, and mouse melanoma models.

Jaroch K, Taczynska P, Czechowska M, Bogusiewicz J, Luczykowski K, Burlikowska K J Pharm Anal. 2021; 11(5):667-674.

PMID: 34765281 PMC: 8572711. DOI: 10.1016/j.jpha.2021.03.005.

Simultaneous silencing of lysophosphatidylcholine acyltransferases 1-4 by nucleic acid nanoparticles (NANPs) improves radiation response of melanoma cells.

Saito R, Rangel M, Halman J, Chandler M, Andrade L, Odete-Bustos S Nanomedicine. 2021; 36:102418.

PMID: 34171470 PMC: 8403145. DOI: 10.1016/j.nano.2021.102418.

References

Croset M, Brossard N, Polette A, Lagarde M . Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J. 1999; 345 Pt 1:61-7. PMC: 1220730. View

Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K . Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 2002; 158(2):227-33. PMC: 2173129. DOI: 10.1083/jcb.200204026. View

Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K . Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem. 2002; 277(42):39436-42. DOI: 10.1074/jbc.M205623200. View

Mills G, Moolenaar W . The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 2003; 3(8):582-91. DOI: 10.1038/nrc1143. View

Matsubara M, Hasegawa K . Benidipine, a dihydropyridine-calcium channel blocker, prevents lysophosphatidylcholine-induced injury and reactive oxygen species production in human aortic endothelial cells. Atherosclerosis. 2004; 178(1):57-66. DOI: 10.1016/j.atherosclerosis.2004.08.020. View

Wang M, Lamers R, Korthout H, van Nesselrooij J, Witkamp R, van der Heijden R . Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res. 2005; 19(3):173-82. DOI: 10.1002/ptr.1624. View

Goffin J, Baral S, Tu D, Nomikos D, Seymour L . Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res. 2005; 11(16):5928-34. DOI: 10.1158/1078-0432.CCR-05-0130. View

Markovic S, Erickson L, Rao R, Weenig R, Pockaj B, Bardia A . Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc. 2007; 82(3):364-80. DOI: 10.4065/82.3.364. View

Zhao Z, Xiao Y, Elson P, Tan H, Plummer S, Berk M . Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol. 2007; 25(19):2696-701. DOI: 10.1200/JCO.2006.08.5571. View

10.

Kaddurah-Daouk R, Kristal B, Weinshilboum R . Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008; 48:653-83. DOI: 10.1146/annurev.pharmtox.48.113006.094715. View

11.

Spratlin J, Serkova N, Eckhardt S . Clinical applications of metabolomics in oncology: a review. Clin Cancer Res. 2009; 15(2):431-40. PMC: 2676437. DOI: 10.1158/1078-0432.CCR-08-1059. View

12.

Park C, Kim M, Han J, Jeong T, Sok D . Lysophosphatidylcholine exhibits selective cytotoxicity, accompanied by ROS formation, in RAW 264.7 macrophages. Lipids. 2009; 44(5):425-35. DOI: 10.1007/s11745-009-3286-6. View

13.

Schmitz G, Ruebsaamen K . Metabolism and atherogenic disease association of lysophosphatidylcholine. Atherosclerosis. 2009; 208(1):10-8. DOI: 10.1016/j.atherosclerosis.2009.05.029. View

14.

Huang L, Hung N, Sok D, Kim M . Lysophosphatidylcholine containing docosahexaenoic acid at the sn-1 position is anti-inflammatory. Lipids. 2010; 45(3):225-36. DOI: 10.1007/s11745-010-3392-5. View

15.

Hung N, Kim M, Sok D . Mechanisms for anti-inflammatory effects of 1-[15(S)-hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan A-induced peritonitis. Br J Pharmacol. 2010; 162(5):1119-35. PMC: 3051384. DOI: 10.1111/j.1476-5381.2010.01117.x. View

16.

Jantscheff P, Schlesinger M, Fritzsche J, Taylor L, Graeser R, Kirfel G . Lysophosphatidylcholine pretreatment reduces VLA-4 and P-Selectin-mediated b16.f10 melanoma cell adhesion in vitro and inhibits metastasis-like lung invasion in vivo. Mol Cancer Ther. 2011; 10(1):186-97. DOI: 10.1158/1535-7163.MCT-10-0474. View

17.

Dunn W, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N . Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 2011; 6(7):1060-83. DOI: 10.1038/nprot.2011.335. View

18.

Zhou X, Lawrence T, He Z, Pound C, Mao J, Bigler S . The expression level of lysophosphatidylcholine acyltransferase 1 (LPCAT1) correlates to the progression of prostate cancer. Exp Mol Pathol. 2011; 92(1):105-10. PMC: 3294031. DOI: 10.1016/j.yexmp.2011.11.001. View

19.

Kruijff S, Hoekstra H . The current status of S-100B as a biomarker in melanoma. Eur J Surg Oncol. 2012; 38(4):281-5. DOI: 10.1016/j.ejso.2011.12.005. View

20.

Buriani A, Garcia-Bermejo M, Bosisio E, Xu Q, Li H, Dong X . Omic techniques in systems biology approaches to traditional Chinese medicine research: present and future. J Ethnopharmacol. 2012; 140(3):535-44. DOI: 10.1016/j.jep.2012.01.055. View